NCT02642042 2026-03-04Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting60 enrolled 24 charts
NCT03340506 2026-02-03Dabrafenib and/or Trametinib Rollover StudyNovartisPhase 4 Recruiting100 enrolled
NCT03225664 2026-01-16Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally AdvancedM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting37 enrolled
NCT04452877 2026-01-13A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCNovartisPhase 2 Completed40 enrolled 17 charts